These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 10731310)

  • 1. Post-marketing surveillance and adverse drug reactions.
    Shani S
    Isr Med Assoc J; 1999 Oct; 1(2):117-9. PubMed ID: 10731310
    [No Abstract]   [Full Text] [Related]  

  • 2. The need for a post-marketing surveillance program in Israel.
    Shemer J
    Isr Med Assoc J; 1999 Oct; 1(2):98-9. PubMed ID: 10731306
    [No Abstract]   [Full Text] [Related]  

  • 3. The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).
    Doshi A
    Seton Hall Law Rev; 2007; 37(2):625-60. PubMed ID: 17294569
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse drug reactions in elderly patients: alternative approaches to postmarket surveillance.
    Noah BA; Brushwood DB
    J Health Law; 2000; 33(3):383-454. PubMed ID: 11184355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 6. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 7. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reform of drug regulation--beyond an independent drug-safety board.
    Ray WA; Stein CM
    N Engl J Med; 2006 Jan; 354(2):194-201. PubMed ID: 16407517
    [No Abstract]   [Full Text] [Related]  

  • 9. Reporting of adverse drug events: a key to postmarketing drug safety.
    Rheinstein PH
    Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 11. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
    Browar S
    Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug safety. Gaps in the safety net.
    Couzin J
    Science; 2005 Jan; 307(5707):196-8. PubMed ID: 15653480
    [No Abstract]   [Full Text] [Related]  

  • 14. MedWatch targets reporting of serious adverse events.
    VanAmringe M
    Jt Comm Perspect; 1993; 13(4):15. PubMed ID: 10129237
    [No Abstract]   [Full Text] [Related]  

  • 15. Vaccine adverse event reporting: the importance of follow-up.
    Varricchio F
    Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
    [No Abstract]   [Full Text] [Related]  

  • 16. Toward improved adverse event/suspected adverse drug reaction reporting.
    Gross R; Strom BL
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):89-91. PubMed ID: 12642971
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEDWatch: the new FDA medical products reporting program.
    Kessler DA
    Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
    [No Abstract]   [Full Text] [Related]  

  • 19. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MedWatch. On lookout for medical product problems.
    Ropp KL
    FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.